Trial Profile
A retrospective study evaluating real world efficacy of fulvestrant monotherapy as first hormone therapy in metastatic breast cancer patients.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Jun 2017
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 02 Jun 2017 Results assessing efficacy of fulvestrant monotherapy as first hormonal therapy, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 02 Jun 2017 New trial record